The c-Met Inhibitors: A New Class of Drugs in the Battle Against Advanced Nonsmall- Cell Lung Cancer

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|18|37|6155-6168

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.18, Iss.37, 2012-12, pp. : 6155-6168

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Role of cMet in Non-Small Cell Lung Cancer Resistant to EGFRInhibitors: Did We Really Find the Target?

By  

Current Drug Targets, Vol. 15, Iss. 14, 2014-12 ,pp. : 1284-1292

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical Pharmacology of EGFR/Met Inhibitors in Non-Small Cell Lung Cancer

By  

Current Drug Targets, Vol. 15, Iss. 14, 2014-01 ,pp. : 1263-1272

Bentham Science Publishers

Access to resources Recommend Favorite

Emerging drugs for non-small cell lung cancer

By Cappuzzo Federico   Bartolini Stefania   Crinò Lucio  

Expert Opinion on Emerging Drugs, Vol. 8, Iss. 1, 2003-05 ,pp. : 179-192

Informa Healthcare

Access to resources Recommend Favorite

Taxanes for advanced non-small cell lung cancer

By Ramalingam Sakkaraiappan   Belani Chandra P  

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 12, 2002-12 ,pp. : 1693-1709

Informa Healthcare

Access to resources Recommend Favorite

Pemetrexed in advanced non-small cell lung cancer

By Gridelli Cesare   Maione Paolo   Rossi Antonio   Bareschino Maria Anna   Schettino Clorinda   Sacco Paola Claudia   Zeppa Rosario  

Expert Opinion on Drug Safety, Vol. 10, Iss. 2, 2011-03 ,pp. : 311-317

Informa Healthcare

Access to resources Recommend Favorite